U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06975579) titled 'The COherence of Scatter Identification and Exclusion Algorithm Study' on May 02.
Brief Summary: Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver condition worldwide; approximately 55% of the world population will have NAFLD by 2040. NAFLD is an unwanted side effect of common cancer therapies, such as chemotherapy. Ultrasound can detect NAFLD via measurement of the backscatter coefficient (BSC). It is an attractive technique because of its low cost and availability, potentially enabling earlier detection of NAFLD in a larger population through screening. This approach has shown promise in detecting NAFLD b...